Cidara rises after US FDA grants 'breakthrough tag' to flu prevention drug

Cidara Therapeutics

09/10/2025 13:39

** Cidara CDTX.O shares rise 3.54% to $102 premarket

** Co says U.S. Food and Drug Administration has granted "breakthrough therapy" designation to its experimental drug, CD388, aimed at preventing influenza A and B in people at high risk of severe illness

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need

** CDTX says mid-stage trial showed CD388 helped prevent seasonal flu in healthy adults

** CD388 is designed to prevent flu without relying on immune response, CDTX says

** Antiviral drug targets high-risk groups, including older adults and those with chronic health conditions or weakened immune systems

** Up to last close, stock up ~266% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com;))